BVNRY:OTC-Bavarian Nordic A/S (USD)

COMMON STOCK | Biotechnology | OTC

Last Closing Price

USD 17.85

Change

0.00 (0.00)%

Market Cap

USD 3.41B

Volume

300.00

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; monkeypox under the JYNNEOS name; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN (freeze-dried) that is in Phase III clinical trials for the treatment of smallpox; MVA-BN RSV, which is in Phase II clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that is in Phase I/II clinical trial for the treatment of SARS-CoV-2; TAEK-VAC, which is in Phase I/II clinical trial for treatment of advanced HER2- and brachyury-expressing cancers; and MVA-BN WEV that is in Phase I clinical trial for treating Equine encephalitis.It has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. The company operates in the United States, Germany, the Netherlands, Sweden, Switzerland, Austria, the United Kingdom, Japan, Canada, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is based in Hellerup, Denmark.

Company Website : http://www.bavarian-nordic.com

Address : Philip Heymans Alle 3, Hellerup, Denmark, 2900

Employees : 730

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 1.47

52 Week High : 19.25

52 Week Low : 9.18

200 Day Moving Average : 15.22

50 Day Moving Average : 17.08

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-09-26 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NONOF Novo Nordisk A/S

N/A

 USD232.05B 33.86 3.79
CMXHF CSL Limited

N/A

 USD103.74B 43.22 29.42
CSLLY CSL Limited

N/A

 USD103.74B 43.33 29.42
WXIBF WuXi Biologics (Cayman) Inc

N/A

 USD64.56B 152.22 28.65
WXXWY WuXi Biologics (Cayman) Inc

N/A

 USD64.12B 151.57 28.65
GNMSF Genmab A/S

N/A

 USD29.37B 74.77 8.17
UCBJY UCB SA

N/A

 USD21.18B 19.78 14.67
UCBJF UCB SA

N/A

 USD21.09B 19.61 14.67
SBHMY Sino Biopharmaceutical Limited

N/A

 USD16.22B 10.75 2.15
SBMFF Sino Biopharmaceutical Limited

N/A

 USD15.66B 10.39 2.15

ETFs Containing BVNRY

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 66.05% 80% B- 79% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 66.05% 80% B- 79% C+
Trailing 12 Months  
Capital Gain 62.27% 71% C- 69% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 62.27% 71% C- 67% D+
Trailing 5 Years  
Capital Gain 37.31% 68% D+ 58% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 37.31% 67% D+ 57% F
Average Annual (5 Year Horizon)  
Capital Gain 4.66% 32% F 37% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.66% 32% F 33% F
Risk Return Profile  
Volatility (Standard Deviation) 44.63% 73% C 53% F
Risk Adjusted Return 10.45% 34% F 30% F
Market Capitalization 3.41B 92% A- 77% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 10.02 64% D 63% D
Price/Book Ratio 3.76 62% D- 30% F
Price / Cash Flow Ratio 5.96 15% F 26% F
EV/EBITDA 18.40 36% F 20% F
Management Effectiveness  
Return on Equity -11.40% 77% C+ 30% F
Return on Invested Capital 8.41% 60% D- 69% D+
Return on Assets -3.04% 82% B- 40% F
Debt to Equity Ratio 8.04% 43% F 68% D+
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 1.47 28% F 27% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.